Kovitz Investment Group Partners LLC Sells 3,036 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Kovitz Investment Group Partners LLC cut its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 17.0% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,793 shares of the medical research company's stock after selling 3,036 shares during the quarter. Kovitz Investment Group Partners LLC's holdings in IQVIA were worth $3,505,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. PGGM Investments raised its holdings in IQVIA by 55.8% in the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company's stock worth $2,553,000 after purchasing an additional 4,326 shares in the last quarter. Simplify Asset Management Inc. increased its stake in shares of IQVIA by 67.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company's stock worth $2,284,000 after acquiring an additional 3,894 shares in the last quarter. Raymond James & Associates increased its stake in shares of IQVIA by 0.7% in the 2nd quarter. Raymond James & Associates now owns 800,374 shares of the medical research company's stock worth $169,231,000 after acquiring an additional 5,417 shares in the last quarter. Versor Investments LP bought a new position in shares of IQVIA in the 3rd quarter worth about $1,328,000. Finally, Gradient Investments LLC increased its stake in shares of IQVIA by 15.6% in the 2nd quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company's stock worth $9,600,000 after acquiring an additional 6,134 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on IQV shares. Deutsche Bank Aktiengesellschaft decreased their price target on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating for the company in a research note on Friday, November 1st. Leerink Partners reiterated an "outperform" rating and issued a $248.00 price target (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Robert W. Baird reduced their price objective on shares of IQVIA from $256.00 to $223.00 and set a "neutral" rating for the company in a research note on Friday, November 1st. Truist Financial reduced their price objective on shares of IQVIA from $286.00 to $265.00 and set a "buy" rating for the company in a research note on Monday, November 4th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $270.00 price objective on shares of IQVIA in a research note on Wednesday, December 4th. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, IQVIA has a consensus rating of "Moderate Buy" and a consensus target price of $256.50.

IQVIA Stock Performance

Shares of IQVIA stock traded up $3.94 during trading hours on Monday, reaching $206.57. 1,748,952 shares of the stock traded hands, compared to its average volume of 1,182,643. The company has a 50 day moving average price of $214.57 and a 200 day moving average price of $224.96. The firm has a market capitalization of $37.49 billion, a price-to-earnings ratio of 27.11, a P/E/G ratio of 2.08 and a beta of 1.49. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.